MAPS Marks 40 Years with $150M Raised as Psychedelic Industry Faces Accessibility Challenges
Event summary
- MAPS celebrates its 40th anniversary, having raised $150M and supported 45 studies since 1986.
- New Executive Order in April 2026 accelerates federal research and regulatory approval for psychedelic therapies.
- MAPS transitions to shared leadership with Betty Aldworth and Ismail Lourido Ali as Co-Executive Directors.
- Organization warns of potential loss of therapeutic integrity as commercial interests prioritize cost-cutting over healing.
The big picture
MAPS' 40-year milestone coincides with a pivotal shift in the psychedelic industry, where scientific progress and policy changes are accelerating. However, the organization cautions that legal access alone is insufficient without ensuring equitable distribution and maintaining therapeutic integrity. The transition to shared leadership reflects a strategic pivot toward sustainable growth and broader societal impact.
What we're watching
- Therapeutic Integrity
- Whether commercial models will prioritize cost-cutting over the therapeutic components essential for long-term healing benefits.
- Equitable Access
- How policy decisions on insurance coverage, training standards, and participant eligibility will shape access to psychedelic therapies.
- Policy Reform
- The pace at which broader legal reforms, including decriminalization and protections for Indigenous communities, advance alongside medical access.